Immunic, inc. to participate in scientific and investor conferences in october

New york, sept. 28, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in october: october 6-7: b &t cell-mediated autoimmune disease drug development summit.
IMUX Ratings Summary
IMUX Quant Ranking